Inhibiting deubiquitinase (DUB) function is a promising strategy for the treatment of cancers and other human diseases. Of the hundreds of human DUBs, USP11 has emerged as an ideal therapeutic target, as it regulates DNA doublestrand break repair by homologous recombination (HR) and other functions central to eukaryotic cell survival. A new study by Spiliotopoulos et al. cleverly uses next-generation phage display (NGPD) to identify peptide ligands that bind USP11 in a unique pocket that impacts HR. The study provides an important step toward novel DUB inhibitors that may reduce the resistance of some cancers to current treatment options.
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The ubiquitin-proteasome system (UPS) 2 is an attractive target for the development of therapeutic agents, as it is needed for important processes in the human cell such as cell cycle progression and stress response. While proteasome inhibitors (e.g. bortezomib and carfilzomib) are successful in the treatment of multiple myeloma and mantle cell lymphoma, these drugs inhibit the 20S proteolytic core of the UPS and, thus, are relatively nonspecific and quite toxic. To enhance specificity, second generation inhibitors that are directed toward upstream components of the UPS machinery, such as ubiquitination, are desired. Ubiquitination, the covalent ligation of ubiquitin (often in chains) to substrate proteins, is reversible and diverse in its targeting proteins for destruction by proteasomes and lysosomes, promoting autophagic clearance of organelles, and regulating protein activity, cellular localization, and complex formation. Cells rely upon a balance in ubiquitination between ubiquitin attachment via E1-E2-E3 enzymes and ubiquitin removal by deubiquitinases (DUBs), with these enzymes considered fair targets for drug development.
While the human genome encodes ϳ100 DUB homologs, including over 50 ubiquitin-specific protease (USP) family members that have a common core with a conserved Cys-His-(Asp/Asn) catalytic triad, USP11 has emerged as a promising target for drug development. Most notably, USP11 is involved in regulating DNA double-strand break repair by homologous recombination (HR) (1), but is also putatively associated with several other pathways. Importantly, USP11 knockdown deregulates HR-mediated DNA repair and sensitizes cells to ionizing radiation (2) and genotoxic agents (3, 4) . Thus, while USP11specific inhibitors are not yet available, it is thought they could assist in the battle against some cancers (3, 4) . The challenge is that USP11-specific interaction sites are not well defined, and no USP11-specific ligands exist.
To help resolve this issue, Dreveny and colleagues (5) use a new strategy to search for novel ligands that bind an accessory domain of USP11. This group had previously determined the X-ray crystal structure of the USP11 N-terminal domain and showed that this region had little impact on the isopeptidase activity of this DUB (6) . Since the domain was also not closely related to USP4 and USP15 paralogs, they speculated it would be a good starting point to identify unique peptide ligands specific to USP11. To explore this idea, the authors used a next-generation phage display (NGPD) strategy ( Fig. 1 ), traditionally reserved for epitope mapping. The strength of this technique is that all of the hits are able to be sequenced, enabling a much deeper analysis of successful sequences than the standard plating assays. This approach enabled the researchers to identify peptide ligands that selectively bound the USP11 domain; the associated phage were isolated, sequenced, and rank-ordered to ultimately identify two motifs for the putative peptide ligands.
Spiliotopoulos et al. (5) next analyzed two prototype peptides for USP11 binding and function. In vitro, the peptides bound USP11 with an equilibrium dissociation constant (K D ) of ϳ10 M, and were specific, unable to bind the USP4 and USP15 paralogs. This level of ligand affinity encouraged the researchers to determine the X-ray crystal structure of the peptide bound to the USP11 domain. From this structure, a unique and previously unrecognized paralog-specific pocket in the N-terminal ubiquitin-like domain of USP11 was found to bind the peptide ligands. A bidentate-like interaction was observed that included USP11 residues forming major and minor hydrophobic pockets as well as a salt bridge "second-tooth." By comparison, steric clashes occurred when the peptide was modeled into the comparable regions of USP4 and USP15. To further investigate, the authors made USP11 L208F and S242R substitutions that rendered this pocket USP15-like and unable to bind the peptide. The amino acid exchanges had no apparent impact on the folding or hydrodynamic radius of USP11 and did not alter USP11-mediated cleavage of a model substrate. However, in vivo, the substituted USP11 was no longer able to function in HR. Finally, transduction of a modified peptide agent was found to have a differential effect on cell viability compared with a scrambled control peptide. Overall, the USP11 pocket and peptide ligand were found to be associated with HR-mediated DNA repair and impaired cell viability in a surprisingly cell-type-specific manner that was associated with cell-cycle arrest and S-phase progression. The model that emerges from these experiments is that the peptides binding in the newly identified pocket impacts the association of USP11 with protein partners. An important next step for this work is to directly test this model; if it proves accurate, deciphering the molecular mechanism of this inhibition and the protein partners that are impacted would greatly bolster understanding of USP11 function. Like most DUBs, USP11 is a large multidomain protein that binds a wide variety of proteins either directly or indirectly, with the direct interaction sites yet to be established. While the C-terminal domain of USP11 binds protein partners such as VGLL4 and VSP11 (7, 8) , the precise site of this binding is unknown. Furthermore, while the N-terminal domains of USP4 and USP15 mediate interactions with protein partners, the role of USP11's N-terminal domain is unknown. To further complicate the matter, USP11 is antagonized by multiple E3 ligases (9), suggesting transient interactions, and USP11 phosphorylation (at Ser-453) enhances its binding properties toward certain substrates (10) . Thus, knowledge of USP11 sites that directly interact with protein partners is needed to improve inhibitor design.
Overall, this study provides an important step toward generating DUB inhibitors that may overcome the resistance of certain cancers to genotoxic agents, such as PARP inhibitors and SMAC mimetics. However, one big challenge to this approach is that most interaction studies are based on co-purification from cells and, thus, do not distinguish the direct contact sites that would aid in inhibitor design. The use of NGPD provides a creative example of how co-opting strategies optimized for other applications can help to address this and other challenges in DUB ligand discovery. Figure 1 . The NGPD strategy used to discover peptide ligands of USP11. The N-terminal domain of USP11 was immobilized on cobalt beads and mixed with a phage display library of randomized linear peptides. Peptides displayed on the phage that bound the USP11 fragment were enriched by repeated washing, elution, amplification, and binding. Phage selected by this approach were isolated, and the associated single-stranded DNA was sequenced. The DNA sequences were ranked by relative statistical importance and analyzed for encoded peptide motifs. Peptides based on these motifs were synthesized and analyzed for USP11 binding and impact on cell viability.
